Cardiovascular Effects of Non-Selective Monoamine Oxidase Inhibitors and Intranasal Esketamine Combination in Depression - A Quasi-Experimental Design with Bayesian Analyses.
Pharmacopsychiatry June 2, 2025 Ludovic C Dormegny-Jeanjean, Suzie Lenoir, Ilia Humbert et al. 1 citation
Ketamine and esketamine (ESK) offer new treatment options for resistant depression. Unlike traditional antidepressants, they can be used in combination with non-selective monoamine oxidase inhibitors (NS-MAOI) without the risk of serotonergic syndrome. However, potential sympathomimetic synergy may lead to elevated blood pressure (BP). This series investigates whether cardiovascular parameters...
DOI: 10.1055/a-2590-3469 (opens in new tab)
Full text (opens in new tab)
Depression
Antidepressants
Mental health
Medical research
+1